Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
Vera Therapeutics, Inc. Frequently Asked Questions
What is the ticker symbol for Vera Therapeutics, Inc.? What does VERA stand for in stocks?
VERA is the stock ticker symbol of Vera Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.
What is the market capital of Vera Therapeutics, Inc. (VERA)?
As of Wed Dec 04 2024, market cap of Vera Therapeutics, Inc. is 3.13 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.
What is the fair value of VERA stock?
You can check VERA's fair value in chart for subscribers.
Is Vera Therapeutics, Inc. a good stock to buy?
The fair value guage provides a quick view whether VERA is over valued or under valued. Whether Vera Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Vera Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VERA.